Quarterly ResultMay 7, 2026, 04:02 PM
Inmune Bio Q1 Net Loss $5.4M; XPro™ FDA Path; CORDStrom™ UK MAA
AI Summary
INmune Bio Inc. reported a reduced net loss of $5.4 million for Q1 2026, significantly down from $9.7 million in Q1 2025, driven by lower research and development expenses. The company achieved key regulatory milestones, including FDA alignment for an adaptive Phase 2b/3 registrational pathway for XPro™ in early Alzheimer's Disease. Additionally, the CORDStrom™ program is on track for MAA submission to the UK MHRA in mid-summer, with subsequent EMA and FDA BLA submissions anticipated.
Key Highlights
- Net loss attributable to common stockholders was $5.4 million for Q1 2026, down from $9.7 million in Q1 2025.
- Research and development expenses decreased to $3.6 million in Q1 2026 from $7.6 million in Q1 2025.
- General and administrative expenses were $2.2 million in Q1 2026, compared to $2.3 million in Q1 2025.
- FDA aligned with an adaptive Phase 2b/3 registrational pathway for XPro™ in early Alzheimer's Disease.
- CORDStrom™ MAA submission to UK MHRA is on target for mid-summer, followed by EMA filing.
- CORDStrom™ Biologics License Application (BLA) submission to the FDA is expected in Q4 2026.
- The company had approximately 26.6 million common shares outstanding as of May 7, 2026.